Key facts & figures
Sanofi is a diversified global healthcare company engaged in the research, development, manufacture and marketing of healthcare products. Our business includes pharmaceuticals (prescription drugs, consumer healthcare and generics), vaccines and animal health.
|€ million||2012 net sales||Change at CER||H1 2013 net sales||Change at CER|
excluding Diabetes, Vaccines, CHC, Animal Health,
New Genzyme and Other Innovative Products
|Other Innovative Products***||611||+10.5%||328||+14.1%|
|Total Growth Platforms||23,548||+9.9%||11,441||+5.4%|
|Total Growth Platforms with Genzyme pro forma||23,548||+7.8%|
|Total Growth Platforms
Change excluding Brazil generics
* Include Diabetes, Vaccines, Consumer Healthcare, Animal Health, Genzyme and Other Innovative Products sales generated in Emerging Market.
** On a constant structure basis and at constant exchange rates.
*** Includes recent product launches which do not belong to the other Growth Platforms listed above: Multaq®, Jevtana®, Zaltrap®, and Mozobil® pro forma.
Sanofi's pharmaceuticals business notably focuses on diabetes, rare diseases, oncology, and other flagship products in anti-thrombotics, cardiovascular, renal and biosurgery fields.
It also includes Consumer Healthcare, one of our important growth platforms.
In addition, our pharmaceuticals portfolio comprises Generics.
Sanofi Pasteur, the fully integrated Vaccines business of Sanofi, is a world leader in the vaccines industry offering a large range of vaccines covering 20 serious infectious diseases.
Our Animal Health activity is carried out through Merial, that is one of the world’s leading animal healthcare companies dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines used by veterinarians, farmers and pet owners.
Sanofi has a commercial presence in approximately 100 countries, and our products are available in more than 170 countries.
Sanofi is the established leader in Emerging Markets, holding top positions in the main countries. In 2012, Emerging Markets totaled €11,145 million, an increase of 8.3%. Emerging Markets sales contribute to 31.9% of Group sales and are the most important contributors to the region sales.
In H1 2013, Emerging Markets totaled €5,388 million, an increase of 1.9% (+6.6% excluding Brazil generics).
Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013
© Sanofi 2004-2013 - All rights reserved - Update: October 24, 2013